NeOnc to acquire AI, 3D, quantum modeling IP portfolio from Puri

NeOnc Technologies (NTHI) announces the signing of a definitive, binding Letter of Intent, LOI, to acquire all outstanding equity interests in a to-be-formed Delaware entity jointly owned by Dr. Ishwar Puri and Beth Levinson. The IP portfolio, which includes U.S. Patent No. 11,788,057 B2, secured through a Patent Transfer Agreement with McMaster University, features 3D bioprinting, artificial intelligence, and quantum modeling technologies designed to accelerate preclinical drug discovery and high-throughput screening of brain-targeted therapies. These assets will be integrated into NeOnc’s expanding IP platform and will be also part of NeOnc’s Middle East partnership with Quazar Investment Group, which is designed to help drive global innovation and clinical trial execution across the GCC region.